TCRXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer...

Stats
本日の出来高	92 052.00
平均出来高	196 857
時価総額	319.19M
EPS	$0 ( 2024-03-13 )
次の収益日	( $-0.250 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.42
ATR14	$0.0240 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Baker Bros. Advisors Lp	Buy	8 851 451	Warrants to purchase Common Stock
2024-04-19	Baker Bros. Advisors Lp	Buy	825 968	Warrants to purchase Common Stock
2024-04-19	Lynx1 Capital Management Lp	Buy	5 000 000	Pre-funded Warrant (right to buy)
2024-02-01	Amello Jason	Buy	750 000	Stock Option (Right to Buy)
2024-01-29	Amello Jason	Buy	0

INSIDER POWER
99.17
Last 93 transactions
Buy: 66 481 256 \| Sell: 5 443 695

ボリューム相関

長: -0.10 (neutral)

短: -0.69 (moderate negative)

Signal:(43.678) Neutral

TScan Therapeutics, Inc. 相関

10 最も正の相関
CRSA	0.871
HALL	0.871
MVBF	0.868
SNCR	0.859
OSMT	0.857
MYNA	0.84
SOUN	0.839
KFRC	0.824
LMFA	0.823
LMNL	0.819

10 最も負の相関
SLVO	-0.879
BNIXU	-0.864
BMRN	-0.85
ARTNA	-0.848
MRNA	-0.839
FNKO	-0.838
CAMP	-0.836
FNWD	-0.823
AVDX	-0.815

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

TScan Therapeutics, Inc. 相関 - 通貨/商品

0.18
( neutral )

0.16
( neutral )

0.00
( neutral )

0.30
( neutral )

0.06
( neutral )

-0.33
( neutral )

TScan Therapeutics, Inc. 財務諸表

Annual	2023
収益:	$21.05M
総利益:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2023
収益:	$21.05M
総利益:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2022
収益:	$13.54M
総利益:	$8.40M (62.05 %)
EPS:	$-2.74

FY	2021
収益:	$10.14M
総利益:	$0.00 (0.00 %)
EPS:	$-4.17

Financial Reports:

No articles found.

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.